Logo image of CERS

CERUS CORP (CERS) Stock Fundamental Analysis

NASDAQ:CERS - Nasdaq - US1570851014 - Common Stock - Currency: USD

1.29  -0.01 (-0.77%)

Fundamental Rating

3

CERS gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 191 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of CERS have multiple concerns. CERS is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

CERS had negative earnings in the past year.
In the past year CERS had a positive cash flow from operations.
CERS had negative earnings in each of the past 5 years.
CERS had negative operating cash flow in 4 of the past 5 years.
CERS Yearly Net Income VS EBIT VS OCF VS FCFCERS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

CERS has a better Return On Assets (-10.41%) than 60.73% of its industry peers.
CERS has a Return On Equity of -37.26%. This is comparable to the rest of the industry: CERS outperforms 54.97% of its industry peers.
Industry RankSector Rank
ROA -10.41%
ROE -37.26%
ROIC N/A
ROA(3y)-16.33%
ROA(5y)-19.79%
ROE(3y)-57.26%
ROE(5y)-58.76%
ROIC(3y)N/A
ROIC(5y)N/A
CERS Yearly ROA, ROE, ROICCERS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

CERS's Gross Margin of 59.89% is in line compared to the rest of the industry. CERS outperforms 59.16% of its industry peers.
In the last couple of years the Gross Margin of CERS has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for CERS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 59.89%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.16%
GM growth 5Y-1.44%
CERS Yearly Profit, Operating, Gross MarginsCERS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

3

2. Health

2.1 Basic Checks

CERS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CERS has been increased compared to 1 year ago.
Compared to 5 years ago, CERS has more shares outstanding
The debt/assets ratio for CERS is higher compared to a year ago.
CERS Yearly Shares OutstandingCERS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
CERS Yearly Total Debt VS Total AssetsCERS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -5.13, we must say that CERS is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -5.13, CERS is not doing good in the industry: 66.49% of the companies in the same industry are doing better.
The Debt to FCF ratio of CERS is 9.88, which is on the high side as it means it would take CERS, 9.88 years of fcf income to pay off all of its debts.
CERS has a better Debt to FCF ratio (9.88) than 74.87% of its industry peers.
CERS has a Debt/Equity ratio of 1.16. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of CERS (1.16) is worse than 76.44% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.16
Debt/FCF 9.88
Altman-Z -5.13
ROIC/WACCN/A
WACC10%
CERS Yearly LT Debt VS Equity VS FCFCERS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 2.39 indicates that CERS has no problem at all paying its short term obligations.
The Current ratio of CERS (2.39) is comparable to the rest of the industry.
A Quick Ratio of 1.79 indicates that CERS should not have too much problems paying its short term obligations.
CERS has a Quick ratio of 1.79. This is comparable to the rest of the industry: CERS outperforms 48.17% of its industry peers.
Industry RankSector Rank
Current Ratio 2.39
Quick Ratio 1.79
CERS Yearly Current Assets VS Current LiabilitesCERS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

5

3. Growth

3.1 Past

CERS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 42.11%, which is quite impressive.
CERS shows a small growth in Revenue. In the last year, the Revenue has grown by 7.77%.
Measured over the past years, CERS shows a quite strong growth in Revenue. The Revenue has been growing by 16.50% on average per year.
EPS 1Y (TTM)42.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)7.77%
Revenue growth 3Y8.07%
Revenue growth 5Y16.5%
Sales Q2Q%8.64%

3.2 Future

The Earnings Per Share is expected to grow by 19.86% on average over the next years. This is quite good.
CERS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.84% yearly.
EPS Next Y14.69%
EPS Next 2Y36.75%
EPS Next 3Y19.86%
EPS Next 5YN/A
Revenue Next Year24.85%
Revenue Next 2Y17.47%
Revenue Next 3Y12.84%
Revenue Next 5YN/A

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
CERS Yearly Revenue VS EstimatesCERS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 50M 100M 150M 200M 250M
CERS Yearly EPS VS EstimatesCERS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -0.2 -0.4 -0.6

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

CERS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CERS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CERS Price Earnings VS Forward Price EarningsCERS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30 40

4.2 Price Multiples

81.68% of the companies in the same industry are more expensive than CERS, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 28.12
EV/EBITDA N/A
CERS Per share dataCERS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6 0.8 1

4.3 Compensation for Growth

CERS's earnings are expected to grow with 19.86% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.75%
EPS Next 3Y19.86%

More info and screens

0

5. Dividend

5.1 Amount

CERS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CERUS CORP

NASDAQ:CERS (4/21/2025, 1:36:04 PM)

1.29

-0.01 (-0.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-20 2025-02-20/amc
Earnings (Next)05-01 2025-05-01/amc
Inst Owners76.25%
Inst Owner Change0.01%
Ins Owners4.57%
Ins Owner Change19.1%
Market Cap239.67M
Analysts81.82
Price Target4.34 (236.43%)
Short Float %5.7%
Short Ratio6.68
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)25.32%
Min EPS beat(2)15.99%
Max EPS beat(2)34.64%
EPS beat(4)3
Avg EPS beat(4)18.02%
Min EPS beat(4)-5.03%
Max EPS beat(4)34.64%
EPS beat(8)5
Avg EPS beat(8)19.06%
EPS beat(12)8
Avg EPS beat(12)12.33%
EPS beat(16)11
Avg EPS beat(16)13.34%
Revenue beat(2)1
Avg Revenue beat(2)-0.94%
Min Revenue beat(2)-2.21%
Max Revenue beat(2)0.34%
Revenue beat(4)1
Avg Revenue beat(4)-3.91%
Min Revenue beat(4)-8.57%
Max Revenue beat(4)0.34%
Revenue beat(8)1
Avg Revenue beat(8)-7.14%
Revenue beat(12)5
Avg Revenue beat(12)-2.07%
Revenue beat(16)9
Avg Revenue beat(16)1.09%
PT rev (1m)8.97%
PT rev (3m)8.97%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-29.23%
EPS NY rev (1m)-17.45%
EPS NY rev (3m)-22.67%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)3.39%
Revenue NY rev (1m)0.28%
Revenue NY rev (3m)7.29%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.19
P/FCF 28.12
P/OCF 21.1
P/B 4.27
P/tB 4.37
EV/EBITDA N/A
EPS(TTM)-0.11
EYN/A
EPS(NY)-0.09
Fwd EYN/A
FCF(TTM)0.05
FCFY3.56%
OCF(TTM)0.06
OCFY4.74%
SpS1.08
BVpS0.3
TBVpS0.3
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -10.41%
ROE -37.26%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 59.89%
FCFM 4.23%
ROA(3y)-16.33%
ROA(5y)-19.79%
ROE(3y)-57.26%
ROE(5y)-58.76%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.16%
GM growth 5Y-1.44%
F-Score5
Asset Turnover1
Health
Industry RankSector Rank
Debt/Equity 1.16
Debt/FCF 9.88
Debt/EBITDA N/A
Cap/Depr 152.94%
Cap/Sales 1.41%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.39
Quick Ratio 1.79
Altman-Z -5.13
F-Score5
WACC10%
ROIC/WACCN/A
Cap/Depr(3y)132.31%
Cap/Depr(5y)95.58%
Cap/Sales(3y)1.64%
Cap/Sales(5y)1.38%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)42.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y14.69%
EPS Next 2Y36.75%
EPS Next 3Y19.86%
EPS Next 5YN/A
Revenue 1Y (TTM)7.77%
Revenue growth 3Y8.07%
Revenue growth 5Y16.5%
Sales Q2Q%8.64%
Revenue Next Year24.85%
Revenue Next 2Y17.47%
Revenue Next 3Y12.84%
Revenue Next 5YN/A
EBIT growth 1Y45.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year187.64%
EBIT Next 3Y60.42%
EBIT Next 5YN/A
FCF growth 1Y117.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y126.31%
OCF growth 3YN/A
OCF growth 5YN/A